Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Hormone Research in Paediatrics

From Developmental Endocrinology to Clinical Research

Guidelines for Authors
www.karger.com/hrp_guidelines

Aim and Scope
Submission
Main Sections
Conditions
Plagiarism Policy
Arrangement
Color Illustrations
References
Page Charges
Digital Object Identifier (DOI)
Supplementary Material
Self-Archiving/Green Open Access, Author's ChoiceTM,
   Funding Organizations (NIH etc.)

Proofs
E-pub First
Reprints
Requirements for Mini Reviews



Aim and Scope

'Hormone Research in Paediatrics' aims to provide rapid publication of clinical investigations, mini reviews and novel insights from clinical experience, as well as experimental and methodological work related to paediatric and adolescent endocrinology. Correspondence is welcome, but publication of letters is at the discretion of the editors.




Submission

Manuscripts written in English should be submitted online:

Should you have any problems with your submission, please contact the Editorial Office at

Manuela Obrist
Editorial Office 'Hormone Research in Paediatrics'
S. Karger AG
P.O. Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1437
Fax +41 61 306 1434
hrp@karger.com




Main Sections

The main sections are:

Original Papers: Any original papers on hormone research are accepted; we particularly welcome papers on developmental and clinical research.

Mini Reviews: Most mini reviews are submitted upon invitation. However, the editors are open to unsolicited mini reviews. All mini reviews are subject to peer review. Please note these Details and Guidelines

Novel Insights from Clinical Experience: We invite contributions to this section that provide novel insight into a clinical problem.

We recognise the value of case reports and thus submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognised clinical scenario or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. Manuscripts revealing novel mechanisms are of particular interest. Papers repeating known phenotypes or mutations in a novel context are not acceptable.

We propose that a highlighted box containing one or two bullet points on ‘Established facts’ and ‘Novel insights’ be placed on the first page of the report. This will reinforce the novelty of the clinical observation.

The manuscript should be presented with an abstract (up to 200 words), brief introduction, case or case series description and results, followed by a discussion. No limits on length or number of references are imposed. Statements for the highlighted box should also be included.

Translational Paediatric Endocrinology: This section is aimed at attracting translational research based on experimental studies in cells or animal models that can have a potential impact on the understanding of pathophysiology and/or the management of children with endocrine diseases. The format should be the same as that used for original papers.

Brief Reports: This section is aimed at attracting papers reporting preliminary research data and pilot studies.
These should be concise papers with findings of interest that can be communicated within the limits of 1,800 words, a maximum of 2 figures or tables and a maximum of 12 references. In the cover letter, the authors should explain why brief reports is the appropriate section for their manuscript. Papers submitted to this new section will be treated with priority in the peer review process and if accepted also in the publication process.



Conditions

All manuscripts are subject to editorial review. The names and addresses of six experts in the appropriate area of research should accompany each manuscript. Selected scientist(s) will be invited to act as referee(s).

Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Hormone Research in Paediatrics' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher.

For legal reasons, we must receive your 'Submission Statement' with your original (hand-written) signature. Please download, print, sign and either fax or scan it to make it legally binding.

It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.




Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.
If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).




Arrangement

Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

ESPE or PES membership: As the page charges are waived in any case for the first paper each year to be published by a member of ESPE or PES, authors who are members of the ESPE or PES should so indicate on the title page.

Key words: For indexing purposes, a list of 5 key words in English is essential.

Abstract: Each paper needs an abstract of up to 200 words. It should be structured as follows:
   Background/Aims: What is the major problem that prompted the study?
   Methods: How was the study done?
   Results: Most important findings?
   Conclusion: Most important conclusion?

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180 x 223 mm) or provide crop marks. On the back of each illustration, indicate its number, the author's name, and ‘top’ with a soft pencil. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800-1200 dpi.




Color Illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.




References

In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as 'unpublished data' and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).
Examples

(a) Papers published in periodicals: Sun J, Koto H, Chung KF: Interaction of ozone and allergen challenges on bronchial responsiveness and inflammation in sensitised guinea pigs. Int Arch Allergy Immunol 1997;112:191–195.

(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

(c) Monographs: Matthews DE, Farewell, VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996.

(d) Edited books: Parren PWHI, Burton DR: Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards antiviral immunotherapy; in Capra JD (ed): Antibody Engineering. Chem Immunol. Basel, Karger, 1997, vol 65, pp 18–56.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.




Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org




Supplementary Material

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.




Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

  • Be used for noncommercial purposes only
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's ChoiceTM (Gold Open Access) articles, see Author's ChoiceTM.


Author's ChoiceTM

Karger’s Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

  • Follow the terms of the relevant Creative Commons license
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.


Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC.
Authors should include information on their grant in the Acknowledgements section of their papers.




Page Charges

There is no page charge for papers of 4 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 650.00. The allotted size of a paper is equal to approx. 12 manuscript pages (including tables, illustrations and references).
As the page charges are waived in any case for the first paper each year to be published by a member of ESPE or PES, authors who are members of the ESPE or PES should so indicate on the title page.




Proofs

Unless indicated otherwise, a PDF for correction is sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.




E-pub First

All articles are published electronically ahead of print with a DOI number and are supplemented later with the definite reference of the printed version. The articles become available immediately after the authors' approval to publication, with the added advantage of being citable much earlier than in print. Authors can influence the time of appearance by promptly returning the proofs.




Reprints

Order form and price list is sent with the PDF. Orders submitted after the issue is printed are subject to considerably higher prices.




Mini Reviews

'Hormone Research in Paediatrics' publishes one or two focused mini reviews in each issue. These mini reviews are aimed at covering a wide range of basic and clinical topics, of interest for its readership. 'Hormone Research in Paediatrics' mini reviews are available to non-subscribers in free access on the web.

Target audience: 'Hormone Research in Paediatrics' readership is composed mainly of pediatric endocrinologists and endocrinologists, dealing with clinical, clinical research or basic research activities. The mini reviews are intended mostly for a clinical readership who may not read the primary literature on basic mechanisms of endocrine diseases, neurosciences and methodological aspects. Therefore, reviewers should avoid technical jargon to increase the accessibility of the text for a general audience.

Contents: Reviews on basic science topics should include clinical applications or clinical perspectives (approx. 1/4th to 1/5th of the manuscript). Conversely, reviews of clinical topics should discuss basic mechanisms relevant to the topic (approx. 1/4th to 1/5th of the manuscript).

Format: The mini review should be about 3,000 words, not including the references. There should be an abstract of no more than 200 words as well as approximately 5 key words. Please add a word count, the number of references, and the number of figures and tables on the title page. The Medline search strategy should be stated in the manuscript. The manuscript should be organized with headings and subheadings to improve readability.

Figures: A maximum of 5 color figures should be included. They should be prepared with great care and should be self-explanatory: they are often the first and sometimes the only part of the review that will be looked at by most readers. There are no charges for color figures.

References: There should be a maximum of 60 references.

Copyright: The authors should state whether they have a similar review in press or in preparation and if so send a copy or an outline of the other review to avoid duplicate publication.

Submission: Most mini reviews are commissioned by the editorial board. However, unsolicited mini reviews are welcome. It is suggested, however, to contact one of the associate editors in charge of the mini reviews

   Faisal Ahmed, Glasgow
   Michel Polak, Paris
   Raimo Voutilainen, Kuopio

before preparing a manuscript or if any questions arise during the preparation of a manuscript. To submit, please use the Online Submission Website